Lung Cancer Therapeutics Market to Reach USD 50.34 Billion by 2030; Poised for Double‐Digit Growth and Biomarker‐Driven Shifts

Mordor Intelligence has published a new report on the "lung cancer therapeutics market" offering a comprehensive analysis of trends, growth drivers, and future projection

Introduction

The lung cancer therapeutics market size is valued at USD 27.89 billion in 2025 and is forecast to reach USD 50.34 billion by 2030, translating into a 12.54% CAGR. Rising lung cancer incidence, broader adoption of precision diagnostics, and accelerating approvals of novel agents are key forces driving this expansion. In particular, non‐small cell lung cancer (NSCLC) continues to command the largest share of therapeutic demand, while small‐cell lung cancer (SCLC) is seeing renewed interest from the innovation pipeline As healthcare systems globally strive to improve patient access, reimbursement expansion in emerging markets supports greater uptake of targeted therapies and immunotherapies. At the same time, market pressures in mature regions are encouraging pricing strategies and novel value frameworks.

Report Overview: https://www.mordorintelligence.com/industry-reports/global-lung-cancer-therapeutics-market-industry?utm_source=openpr

Key Trends in the Lung Cancer Therapeutics Market

Transition toward biomarker‐guided therapies

In recent years, treatment selection in lung cancer has shifted from broad cytotoxic regimens toward mutation‐matched therapies, supported by the expansion of next‐generation sequencing and companion diagnostics. Biomarker stratification (for EGFR, ALK, KRAS, MET, etc.) is now integral to first‐line decision making, which has expanded the addressable population for targeted agents and improved response rates.

Surge in immunotherapy and biologics

While small molecule drugs still represent a large share of the lung cancer therapeutics market by revenue, biologics including monoclonal antibodies and bispecific formats are growing more rapidly. The adoption of immune checkpoint inhibitors and antibody‐drug conjugates is reshaping the competitive balance over time.

Geographic expansion and regional shifts

North America continues to hold the largest share of market revenue, driven by high research capacity, established reimbursement systems, and rapid regulatory pathways . Meanwhile, Asia-Pacific is expected to grow fastest, aided by expanding diagnostic infrastructure, improving reimbursement environments, and increased local innovation in oncology therapeutics .

Escalating competition and patent pressures

As key agents approach patent expiry, biosimilars and next‐generation versions are emerging, intensifying price competition. Some originator firms are responding by bundling therapies or investing in adjacent modalities to protect revenue.

Shift in distribution toward outpatient/retail channels

Historically, hospital pharmacies dominated distribution of lung cancer therapies due to the infusion nature of many regimens. However, the rise of oral targeted agents is enabling greater dispensing in retail and specialty pharmacies, helping to decentralize access and reduce burden on hospital settings.

Check out more details and stay updated with the latest industry trends, including the Japanese version for localized insights:

https://www.mordorintelligence.com/ja/industry-reports/global-lung-cancer-therapeutics-market-industry?utm_source=openpr

Segmentation in the Lung Cancer Therapeutics Market

The lung cancer therapeutics market can be broken down across several dimensions, each reflecting distinct demand and growth patterns. Key segments include:

By Disease Type

Non‐Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

others

By Treatment Modality

Chemotherapy

Immunotherapy

Targeted Therapy

By Drug Class

Small Molecule Agents

Biologics / Biosimilars

By Distribution Channel

Hospital Pharmacies

Retail / Specialty Pharmacies

Online pharmacies

By Line of Therapy

First Line

Second Line

Third Line and Beyond

By Geography

North America

Europe

Asia‐Pacific

Middle East & Africa

South America

Key Players in the Lung Cancer Therapeutics Market

AstraZeneca

Boehringer Ingelheim

Bristol-Myers Squibb Company

Novartis AG

Eli Lilly and Company

Explore more insights on lung cancer therapeutics market competitive landscape: https://www.mordorintelligence.com/industry-reports/global-lung-cancer-therapeutics-market-industry/companies?utm_source=openpr

Conclusion & Outlook

The lung cancer therapeutics market is entering a dynamic phase defined by rising demand for precision care, shifting competitive pressures, and evolving access models. The market is poised for growth driven by biomarker‐guided therapy adoption, immunotherapy expansion, and rising uptake in emerging economies.

However, challenges remain. High drug cost, access inequalities, adverse effects of therapies, and pricing pressures in mature markets must be addressed. Strategic partnerships, flexible pricing models, and wider diagnostic access will be critical to ensure that innovation reaches patients broadly.

For complete market analysis, please visit the Mordor Intelligence page: https://www.mordorintelligence.com/industry-reports/global-lung-cancer-therapeutics-market-industry?utm_source=openpr

Industry Related Reports

Non-Small Cell Lung Cancer (NSCLC) Market: The Non-Small Cell Lung Cancer (NSCLC) Market is Segmented by Histology (Squamous Cell Carcinoma, Adenocarcinoma and More), by Treatment Modality (Surgery, Radiation Therapy and More), by Drug Class (EGFR TKIs, ALK/ROS1/RET Inhibitors and More) and Geography (North America, Europe, Asia-Pacific and More ).

Get More Insights: https://www.mordorintelligence.com/industry-reports/non-small-cell-lung-cancer-market?utm_source=openpr

Protein-Based Cancer Therapeutics Market: The Protein-Based Cancer Therapeutics Market report segments the industry into By Product Type (Monoclonal Antibodies, Hormones, Fusion Proteins, Others), By Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Other Cancer Types), By End User (Hospitals, Ambulatory Surgical Centers, Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, South America).

Get More Insights: https://www.mordorintelligence.com/industry-reports/protein-based-cancer-therapeutics-market?utm_source=openpr

Solid Tumor Therapeutics Market: The Solid Tumor Therapeutics Market Report is Segmented by Cancer Type (Breast Cancer, Lung Cancer, and More), Drug Type (Carboplatin, Cisplatin, and More), Administration Route (Intravenous, Oral, Subcutaneous, Intratumoral, Other Administration Routes), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America).

Get More Insights: https://www.mordorintelligence.com/industry-reports/solid-tumor-therapeutics-market?utm_source=openpr

About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

Mordor Intelligence, 11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli, Hyderabad, Telangana - 500032, India

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

This release was published on openPR.